Compare NVTS & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVTS | INDV |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.7B |
| IPO Year | 2020 | 2014 |
| Metric | NVTS | INDV |
|---|---|---|
| Price | $21.35 | $36.86 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.68 | N/A |
| AVG Volume (30 Days) | ★ 37.9M | 2.0M |
| Earning Date | 05-05-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 0.69 |
| Revenue | $45,916,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $71.28 | N/A |
| P/E Ratio | ★ N/A | $54.88 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $1.88 | $11.07 |
| 52 Week High | $23.82 | $41.00 |
| Indicator | NVTS | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 54.73 |
| Support Level | $7.35 | $34.91 |
| Resistance Level | N/A | $37.83 |
| Average True Range (ATR) | 2.46 | 1.48 |
| MACD | 0.32 | -0.16 |
| Stochastic Oscillator | 74.48 | 42.11 |
Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).